Cholelithiasis
Tirzepatide safe, effective for weight loss, preventing diabetes progression at 3 years
SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the weight-loss medication, a speaker reported.
SELECT ‘legitimized obesity medical therapy’ for treatment of cardiometabolic disease
SAN ANTONIO — The disruptive SELECT trial not only bolstered the idea of medical obesity therapy as an avenue for heart disease prevention, its subanalyses continue to generate interesting new hypotheses, speakers reported.
New CLEAR Outcomes data: Bempedoic acid cuts risk for recurrent CV events
A prespecified analysis of the CLEAR Outcomes trial shows that the benefits of bempedoic acid extend to patients with recurrent CV events, including a total reduction in MI risk of 31% vs. placebo.
Gallstone disease may be predictor of pancreatic cancer
Patients with pancreatic ductal adenocarcinoma were six times more likely to have had cholelithiasis or cholecystitis in the year before diagnosis compared with the general population, according to data presented at Digestive Disease Week.